Zoetis Inc (ZTS)

Currency in USD
81.03
-0.97(-1.18%)
Closed·
80.50-0.53(-0.65%)
·
Advertisement
Earnings results expected in 13 days
ZTS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
80.6081.86
52 wk Range
68.77147.93
Key Statistics
Prev. Close
82
Open
81.14
Day's Range
80.6-81.86
52 wk Range
68.77-147.93
Volume
1.91M
Average Volume (3m)
5.12M
1-Year Change
-44.6479%
Book Value / Share
7.51
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZTS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
93.00
Upside
+14.77%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Zoetis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

6 Buy
11 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 93.00
(+14.77% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Hold---Downgrade20/10/2026
Goldman Sachs
Hold74.00-8.68%-New Coverage16/10/2026
Stifel
Hold80.00-1.27%-Maintain18/09/2026
TD Cowen
Buy94.00+16.01%104.00Maintain25/08/2026
Stifel
Hold80.00-1.27%85.00Maintain20/08/2026

Zoetis Inc SWOT Analysis


Market Leadership
Zoetis maintains dominance in animal health, with a robust portfolio spanning companion animal and livestock sectors, despite increasing competition
Financial Resilience
Analysts project continued growth, with Q3 2024 organic revenue expected to rise 9.2%. Price targets range from $225 to $242, reflecting positive outlook
Product Innovation
Explore Zoetis's key growth drivers, including Librela for canine osteoarthritis and Apoquel for dermatology, alongside a promising pipeline in oncology and cardiology
Future Prospects
Delve into Zoetis's strategies for tapping untapped markets in animal anti-depressants and pain management, while navigating challenges like foreign exchange impacts
Read full SWOT analysis

Zoetis Inc Earnings Call Summary for Q2/2026

  • Zoetis Q2 EPS of $1.87 beat estimates by $0.01, but revenue of $2.5B missed forecasts by $10M, falling 1% organically year-over-year.
  • Full-year 2026 guidance cut: revenue now $9.12B-$9.32B, EPS $6.15-$6.25, citing weak companion-animal demand and FX headwinds.
  • U.S. revenue dropped 7% while international rose 6%; livestock and diagnostics offset weakness in dermatology and parasiticides.
  • CEO Peck noted 'more competitive and value-conscious environment,' with strategy focused on targeted promotions and cost cuts, not list price reductions.
  • Stock trades at $74.93, near 52-week low of $71.47 and 53% below high of $160.48; offers 5.7% dividend yield with 13 consecutive annual increases.
Last Updated: 06/08/2026, 15:10
Read Full Transcript

Earnings

Latest Release
06/08/2026
EPS / Forecast
1.87 / 1.86
Revenue / Forecast
2.5B / 2.51B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.13
Dividend Yield
2.59%
Industry Median 2.30%
Annualised payout
2.12
Paid quarterly
5-Years Growth
+18.01%
Growth Streak

Compare ZTS to Peers and Sector

Metrics to compare
ZTS
Peers
Sector
Relationship
P/E Ratio
12.7x13.6x−0.3x
PEG Ratio
2.06−0.110.00
Price/Book
10.6x2.3x2.6x
Price / LTM Sales
3.5x2.2x2.9x
Upside (Analyst Target)
13.4%18.1%64.3%
Fair Value Upside
Unlock6.0%9.2%Unlock

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Employees
14500

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
201.66M48.80%16.06B
Other Institutional Investors
205.66M49.77%16.37B
Public Companies & Retail Investors
5.90M1.43%469.60M
Total
413.22M100.00%32.9B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.9.54%39,430,1813,139,431
Vanguard Capital Management, LLC6.87%28,393,8202,260,716

People Also Watch

45.69
BSX
-0.70%
215.48
NTAP
+1.40%
140.16
VST
-0.48%
56.70
HPE
+2.22%
54.24
CRWV
-2.46%

FAQ

What Is the Zoetis Inc (NYSE: ZTS) Share Price Today?

The Zoetis Inc stock price today is 81.03 USD.

What Stock Exchange Does Zoetis Inc (ZTS) Trade On?

Zoetis Inc is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Zoetis Inc?

The stock symbol (also called a 'ticker') for Zoetis Inc is "ZTS."

Does Zoetis Inc Pay Dividends? What’s The Current ZTS Dividend Yield?

Yes, ZTS Pays Dividends to its Shareholders. The current Zoetis Inc dividend yield is 2.6%%.

What Is the Current Zoetis Inc Market Capitalisation?

As of today, Zoetis Inc (NYSE: ZTS) market cap is 33.41B USD.

What Is Zoetis Inc's (ZTS) Earnings Per Share (TTM)?

The Zoetis Inc EPS is currently 6.13 (Trailing Twelve Months).

When Is the Next Zoetis Inc Earnings Date?

Zoetis Inc's next earnings report will be released on 05/11/2026.

Is ZTS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Zoetis Inc moving averages and other technical indicators, the daily buy/sell signal for ZTS stock is Strong Buy.

How Many Times Has Zoetis Inc Stock Split?

Zoetis Inc has split 0 times. (See the ZTS stock split history page for full effective split date and price information.)

How Many Employees Does Zoetis Inc Have?

Zoetis Inc has 14500 employees, based on their latest Companies House report.

What is the current trading status of Zoetis Inc (NYSE: ZTS)?

As of 23/10/2026, Zoetis Inc (ZTS) is trading at a share price of 81.03 USD, with a previous close of 82.00 USD. The stock has fluctuated within a day range of 80.60 USD to 81.86 USD, while its 52-week range spans from 68.77 USD to 147.93 USD.

What Is Zoetis Inc (ZTS) Price Target According to Analysts?

The average 12-month price target for Zoetis Inc is 93.00 USD, with a high estimate of 155 USD and a low estimate of 74 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +14.77% Upside potential.

What Is the ZTS Premarket Price?

ZTS's last pre-market stock price is 81.64 USD. The pre-market share volume is 10,210.00, and the stock has decreased by -0.36, or -0.44%.

What Is the ZTS After Hours Price?

ZTS's last after hours stock price is 80.50 USD, the stock has decreased by -0.53, or -0.65%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.